Connect with us

Company News

Nevro appoints finance executive Roderick MacLeod as CFO

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Roderick (“Rod”) MacLeod as Chief Financial Officer, effective June 15, 2020, with global responsibility for Finance, IT and Customer Service.  Mr. MacLeod succeeds Andrew Galligan, who is retiring but will remain with the Company during a transition period.

“Rod is a proven leader with a track record of success in finance and operations leadership.  We are pleased that Rod is joining the Nevro executive team at a point in our history where his extensive financial, strategic and industry experience will help us accelerate toward long-term sustainable growth and strong financial performance for our shareholders,” said D. Keith Grossman, Chairman, CEO and President, Nevro.

“I’m very pleased to join Nevro and I view this as an exciting opportunity to continue to build a great company while helping patients who suffer from chronic pain,” said Rod MacLeod.  “I look forward to working closely with Keith and the rest of the Nevro team to execute on the Company’s growth strategy.”

Regarding Andrew Galligan’s retirement Grossman added, “Nevro has benefitted tremendously from Andrew’s leadership over the past decade and he has played a vital role in establishing a solid financial and operational foundation for the Company.  On behalf of the entire organization, I want to thank Andrew for his many accomplishments as CFO.  I also want to thank Andrew personally for being a great resource for me as I came on board, and for remaining with the Company during this transition period.”

“I’d like to thank Keith and the entire Nevro team – it’s truly been an honor to be a part of Nevro for these ten years,” said Andrew Galligan, Chief Financial Officer, Nevro.  “I’m proud of all that we’ve accomplished together and I’m confident that the Company is well positioned for future growth and success.” – PRNewswire

Copyright © 2024 Medical Buyer

error: Content is protected !!